Fold expansion and surface marker expression of Venus+ and C/EBPα+ cells after transduction
| Patient no. . | V1: fold expansion . | V2: antigen expression in culture, % . | Increase/decrease in V3 antigen expression, % . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD14 . | CD15 . | CD71 . | CD11b . | CD36 . | CD14 . | CD15 . | CD71 . | CD11b . | CD36 . | ||
| 2 | +20 | +16 | ND | ND | ND | ||||||
| Venus + 4OHT | 3.9 | 0 | 0 | ND | ND | ND | |||||
| C/EBPα + 4OHT | 0.4 | 20 | 16 | ND | ND | ND | |||||
| 3 | +73 | +41 | −7 | ND | +19 | ||||||
| Venus + 4OHT | 28.0 | 15 | 43 | 22 | ND | 2 | |||||
| C/EBPα + 4OHT | 2.2 | 88 | 84 | 15 | ND | 21 | |||||
| 7 | +31 | −5 | −23 | ND | +2 | ||||||
| Venus + 4OHT | 87.5 | 38 | 41 | 37 | ND | 7 | |||||
| C/EBPα + 4OHT | 5.7 | 69 | 36 | 14 | ND | 9 | |||||
| 8 | +40 | +7 | −5 | +25 | +14 | ||||||
| Venus + 4OHT | 863.5 | 3 | 1 | 55 | 66 | 6 | |||||
| C/EBPα + 4OHT | 39.6 | 43 | 8 | 50 | 91 | 20 | |||||
| 9 | +10 | +34 | −13 | ND | −3 | ||||||
| Venus + 4OHT | 4.5 | 12 | 42 | 23 | ND | 7 | |||||
| C/EBPα + 4OHT | 0.4 | 22 | 76 | 10 | ND | 4 | |||||
| 10 | +16 | +11 | −7 | +29 | +7 | ||||||
| Venus + 4OHT | 16.3 | 15 | 0 | 27 | 63 | 3 | |||||
| C/EBPα + 4OHT | 1.5 | 31 | 11 | 20 | 92 | 10 | |||||
| 11 | +2 | −2 | −54 | +24 | −1 | ||||||
| Venus + 4OHT | 154.5 | 1 | 2 | 60 | 65 | 2 | |||||
| C/EBPα + 4OHT | 2.0 | 3 | 0 | 6 | 89 | 1 | |||||
| Patient no. . | V1: fold expansion . | V2: antigen expression in culture, % . | Increase/decrease in V3 antigen expression, % . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD14 . | CD15 . | CD71 . | CD11b . | CD36 . | CD14 . | CD15 . | CD71 . | CD11b . | CD36 . | ||
| 2 | +20 | +16 | ND | ND | ND | ||||||
| Venus + 4OHT | 3.9 | 0 | 0 | ND | ND | ND | |||||
| C/EBPα + 4OHT | 0.4 | 20 | 16 | ND | ND | ND | |||||
| 3 | +73 | +41 | −7 | ND | +19 | ||||||
| Venus + 4OHT | 28.0 | 15 | 43 | 22 | ND | 2 | |||||
| C/EBPα + 4OHT | 2.2 | 88 | 84 | 15 | ND | 21 | |||||
| 7 | +31 | −5 | −23 | ND | +2 | ||||||
| Venus + 4OHT | 87.5 | 38 | 41 | 37 | ND | 7 | |||||
| C/EBPα + 4OHT | 5.7 | 69 | 36 | 14 | ND | 9 | |||||
| 8 | +40 | +7 | −5 | +25 | +14 | ||||||
| Venus + 4OHT | 863.5 | 3 | 1 | 55 | 66 | 6 | |||||
| C/EBPα + 4OHT | 39.6 | 43 | 8 | 50 | 91 | 20 | |||||
| 9 | +10 | +34 | −13 | ND | −3 | ||||||
| Venus + 4OHT | 4.5 | 12 | 42 | 23 | ND | 7 | |||||
| C/EBPα + 4OHT | 0.4 | 22 | 76 | 10 | ND | 4 | |||||
| 10 | +16 | +11 | −7 | +29 | +7 | ||||||
| Venus + 4OHT | 16.3 | 15 | 0 | 27 | 63 | 3 | |||||
| C/EBPα + 4OHT | 1.5 | 31 | 11 | 20 | 92 | 10 | |||||
| 11 | +2 | −2 | −54 | +24 | −1 | ||||||
| Venus + 4OHT | 154.5 | 1 | 2 | 60 | 65 | 2 | |||||
| C/EBPα + 4OHT | 2.0 | 3 | 0 | 6 | 89 | 1 | |||||
Expansion and surface marker expression after transduction. The calculated fold-expansion of transduced cells at week 4, as well as the percentages of cells positive for cell surface markers as measured by flow cytometry are indicated. The arrows indicate the difference in expression between control Venus-transduced cells treated with 500 nM 4-OHT and C/EBPα-ER-transduced cells after 1 week of coculture on MS5 cells.
nd indicates not determined.